Before You Sign: The Document, the Risks, and Who Follows Up

There is a document in front of you, and the first useful question is not what the document is called. It is which situation you are in, because the situation is what decides what the paperwork means and what it has to contain.

Three situations arise in this field, not two, and the middle one is the one people do not know to ask about.

You are being enrolled in a study. The document is a research informed consent form.

An investigational product is being provided to you for treatment, outside a trial. This is expanded access, and it is a regulatory situation rather than a kind of form. It is the middle case because treatment is the purpose while specified research requirements still attach to it. FDA describes the pathway and then states the consequence:

“Sometimes called ‘compassionate use’, expanded access is a potential pathway for a patient with a serious or immediately life-threatening disease or condition to gain access to an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available.”

and

“expanded access to an investigational medical product for treatment use, including emergency use, requires informed consent as described in 21 CFR part 50, unless one of the exceptions found in part 50 applies.”

Source: FDA, Expanded Access: Information for Institutional Review Boards (IRBs). Accessed 18 September 2026.

Read the second sentence. Treatment use of an investigational product still carries the informed consent requirements, because FDA’s consent rules attach to clinical investigations and that term reaches this situation. So “this is treatment, not research” is not by itself a reason for the research protections to be absent. The precise description is narrower than “governed like research”: it is access to an investigational product outside a trial, treated as a clinical investigation for specified regulatory requirements, informed consent among them.

You are being offered a procedure that is neither of the above. The document is ordinary treatment paperwork.

The paperwork for all three can look similar on the page. What is required of it is not the same, and the first question is which situation you are in.

This page shows you how to tell them apart, what to look for in each, where the documented risks are described, and one question that is easy to leave unasked.

Which situation are you in?

Three questions, asked in this order. Each has a factual answer and none of them is difficult to ask.

1. Is this participation in a clinical trial? Look for the word research, study or protocol, a registry number written as NCT followed by digits, a principal investigator or sponsor, or a mention of an institutional review board, usually abbreviated IRB. Those are markers rather than proof, so ask directly.

2. If it is not a trial: is this expanded access, or treatment use of an investigational product? This is the question the other two make people forget, and it is the one that changes which rules apply. Ask it in these words: is the product investigational, and is it being provided under expanded access or under an investigational application? Look for the word investigational, for an IND or IDE number, and for an IRB mention on a document that is otherwise about treatment.

3. If neither: is this ordinary treatment paperwork? A service agreement with fees, scheduling, cancellation and liability terms. That does not make it less important. It means the federal research consent requirements are not the ones that govern it.

The answers determine what follows, so get them before you read anything else in the document. If the answer to question 2 is yes, read the research consent section below as well as the agreement section, because both apply.

The FDA regulations set out what must be present. Consent must be sought:

“only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence.”

and the information must be:

“in language understandable to the subject or the representative.”

Source: FDA, Protection of Human Subjects; Informed Consent. Accessed 18 September 2026.

That first requirement is worth reading twice, because it gets described loosely. It is a requirement that you be given sufficient opportunity to consider. It is a real protection and it applies to research consent.

The regulations also list basic elements that must be present. As the FDA summarises them:

that the study involves research, its purpose, expected duration and procedures, and which procedures are experimental
reasonably foreseeable risks or discomforts
benefits that may reasonably be expected
appropriate alternative procedures or courses of treatment
the extent of confidentiality, and that FDA may inspect records
for research involving more than minimal risk, whether compensation and medical treatment are available if injury occurs
whom to contact with questions and in the event of injury
that participation is voluntary, with no penalty or loss of benefits for declining or withdrawing

These are the FDA’s own headings, in our wording rather than the regulation’s. Read the regulation itself for the exact text; it is linked below.

Use the list as a checklist against the document in your hands. An element that is absent is a question, not a conclusion.

If it is treatment paperwork

The research framework above does not govern this document, so read it as what it is: an agreement.

Where is the product named? Find the full name of what will be administered. Compare it with the name you were told in conversation. If the document uses a general phrase where you were given a specific name, or the reverse, ask which is correct.

Where are the status words? Look for investigational, experimental, or wording stating that a product is not FDA approved. Note where these appear and what they are attached to.

Where is the risk section? Find it and read what it actually lists. Then ask the question that matters more than its length: where does this risk information come from? A risk list with a document behind it can be checked; one that exists only as prose in an agreement cannot. Ask for the source, and compare what is listed against the published list further down this page.

What happens if it does not work? Look for repeat treatment terms, additional fees, and any refund provision. This section carries real financial consequence and it may not come up in conversation at all.

Where are the dispute terms? If the agreement contains arbitration, limitation-of-liability or choice-of-forum language, find it before you sign. This page does not tell you whether such a clause is enforceable or fair, and it does not tell you what rights you have in relation to it. What it tells you is narrower and still useful: these provisions exist, this is where they sit in the document, and they are worth reading before you sign rather than after. If you want to know what a particular clause would mean for you, that is a question for someone qualified to advise on contracts.

For any document you are being asked to sign, ask whether you can have a copy in advance and time to read it. Where that is possible, take it.

One thing worth stating plainly, because this page otherwise only adds to your list: not signing today is an available answer. If the questions above do not have answers yet, that is a reason to leave the document unsigned rather than a gap you have to close before the appointment ends. This is a point about the paperwork in front of you, not about the treatment; whether to have the treatment at all is a conversation with a clinician.

The risks that have been documented

The FDA has published a list of risks associated with unapproved regenerative medicine products. The scope matters, so it is stated before the list: these are described in the context of unapproved products in this field, not as a description of every procedure everywhere.

“Blindness; Tumor formation”

“Bacterial infections including life-threatening blood infections”

“Cells moving to another part of the body and turning into an unintended type of tissue or excessively growing in the body (i.e., forming a tumor)”

“Cross-contamination with bacteria, viruses or mold”

Source for all four: FDA, Important Patient and Consumer Information About Regenerative Medicine Therapies, accessed 18 September 2026. These are described there in the context of unapproved regenerative medicine products.

Two things this list does not do. It does not state how likely any of these are; the source does not give frequencies and neither will we. And it is not the risk profile of every product in this field. For an approved product the risks are described in its labeling. For a product in a registered study they are described in the consent document. For an unapproved product the list above is the published starting point.

So the useful question is not only what the risks are, but where the risk information for this specific product comes from. Ask for that source. A risk list that exists only as a verbal summary has no document behind it.

Who follows you afterwards

This question has consequences long after the appointment ends, which is why it is set out here rather than left to the conversation.

Who is responsible for follow up, and for how long. What the plan is if a complication appears next week, next month, or after the clinic relationship ends. Whether your own regular clinician will receive a record of exactly what was administered. Whether you will leave with documentation that names the product, the date, the dose and the site.

That documentation is not a formality. Someone treating you later may need to know precisely what was given, and a description from memory is a poor substitute.

Questions to bring back

From this page you should have a short written list: which document type, which product name, where the status words sit, what the risk source is, what happens if it does not work, and who follows up.

That list belongs with the questions you take to the consultation, not in a separate place.

Where to go from here

If your list has gaps, the place to convert them into asked questions is Questions to Ask a Regenerative Medicine Clinic, and What a Complete Answer Contains. If you want to check the public record before you go further, see How to Look Up a Clinic’s and a Practitioner’s Public Record.

Before you leave this page: ask whether you can take the document away and read it before signing. Whether or not that is possible, ask who is responsible for follow up and get the answer in writing.

What this does not mean

This page does not give legal advice and does not interpret any contract term. It tells you what to look for in these documents; it does not tell you what they normally contain, and it does not tell you whether any clause is enforceable or reasonable. It does not assess risk for you, and it does not tell you whether to sign anything. It sets out fields and questions to look for, without claiming that every document contains them, and it says where to look. Decisions about treatment and about agreements belong with your clinician and, where terms are in question, with someone qualified to advise on them.

Official sources cited on this page. Every quotation above is taken from one of these. A document quoted in part here is a document worth reading in full before you sign anything.

FDA · Protection of Human Subjects; Informed Consent · accessed 18 September 2026
FDA · Important Patient and Consumer Information About Regenerative Medicine Therapies · accessed 18 September 2026 · the published risk list
FDA · Expanded Access: Information for Institutional Review Boards (IRBs) · accessed 18 September 2026 · the third document type, and the sentence that the consent requirements reach treatment use
FDA · Investigational New Drug (IND) Application · accessed 18 September 2026 · what an IND commits a sponsor to, including consent and IRB review

Written and fact-checked against the sources above on 18 September 2026. No independent expert review has taken place yet, and this page says so rather than implying one. This page is reviewed every twelve months.